American Healthcare REIT (AHR) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

American Healthcare REIT (AHR) reported mixed Q2 2025 results, with revenue of $542.5 million, up 7.5% year-over-year but slightly missing consensus by 0.42%. Conversely, EPS of $0.42 significantly exceeded both the prior year's $0.01 and analyst estimates of $0.40 by 5%. Segment-wise, resident fees and services revenue grew 9.5%, while real estate revenue declined 11.5%. AHR shares have recently outperformed, returning 10% over the past month, and carry a Zacks Rank #2 (Buy), suggesting potential continued market outperformance.

Analysis

American Healthcare REIT (AHR) presented a mixed financial picture for its second quarter of 2025. While headline figures showed a 7.5% year-over-year revenue increase to $542.5 million and a significant EPS beat at $0.42 versus a $0.40 consensus, a deeper look into the underlying metrics reveals areas of concern. Total revenue narrowly missed the Zacks Consensus Estimate by 0.42%. More critically, both key revenue segments underperformed analyst expectations: 'Resident fees and services' revenue of $501.29 million missed the $513.45 million estimate, and 'Real estate revenue' of $41.22 million not only missed its $42.34 million estimate but also declined 11.5% year-over-year. This suggests the 9.5% YoY growth in resident fees is carrying the company's top line. Furthermore, there is a notable discrepancy in earnings, as the reported diluted Net EPS of $0.06 was less than half the two-analyst average estimate of $0.13, contrasting sharply with the positive headline EPS surprise. Despite these operational misses, the stock has rallied 10% in the past month, significantly outperforming the S&P 500, and holds a Zacks Rank #2 (Buy).

Key Decisions for Investors

• Investors should look past the headline EPS beat and scrutinize the underlying operational performance, particularly the revenue miss in both key segments and the significant shortfall in diluted net EPS versus estimates.
• Monitor the divergent performance of AHR's revenue streams, as the 11.5% year-over-year decline in real estate revenue could signal a persistent headwind that may offset growth from resident fees and services.
• Given the stock's strong +10% performance leading into this report, the weaker-than-expected fundamental metrics could make it vulnerable to a reassessment, so caution is warranted despite the positive Zacks Buy rating.